$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

$prta Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000155905318000014 Filed on May 09, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q1
Revenue	$279.0K	$227.0K	$259.0K
YoY Change	-98.96%	-12.36%	-2.26%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$10.99M	$14.23M	$10.83M
YoY Change	0.73%	31.39%	50.84%
% of Gross Profit
Research & Development	$31.45M	$34.71M	$25.70M
YoY Change	-7.58%	35.05%	25.4%
% of Gross Profit
Depreciation & Amortization	$800.0K	$797.0K	$759.0K
YoY Change	0.0%	5.01%	202.39%
% of Gross Profit
Operating Expenses	$63.35M	$48.94M	$36.53M
YoY Change	40.95%	33.96%	32.0%
Operating Profit	-$63.07M	-$48.71M	-$36.27M
YoY Change	247.83%	34.29%	32.33%
Interest Expense	$830.0K	$200.0K	-$360.0K
YoY Change	4050.0%	-155.56%	-228.57%
% of Operating Profit
Other Income/Expense, Net	$1.241M	-$72.00K	-$774.0K
YoY Change	-244.98%	-90.7%	-1205.71%
Pretax Income	-$61.83M	-$48.78M	-$37.05M
YoY Change	225.62%	31.68%	35.5%
Income Tax	-$1.946M	-$37.00K	-$1.661M
% Of Pretax Income
Net Earnings	-$59.88M	-$48.74M	-$35.38M
YoY Change	238.3%	37.75%	28.57%
Net Earnings / Revenue	-21463.08%	-21472.69%	-13661.78%
Basic Earnings Per Share	-$1.50	-$1.26	-$0.99
Diluted Earnings Per Share	-$1.50	-$1.26	-$0.99
COMMON SHARES
Basic Shares Outstanding	39.82M shares	38.54M shares	35.03M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$486.2M	$429.0M	$506.6M
YoY Change	3.07%	-15.32%	6.81%
Cash & Equivalents	$486.2M	$429.0M	$506.6M
Short-Term Investments
Other Short-Term Assets	$7.800M	$8.100M	$7.400M
YoY Change	-20.41%	9.46%	8.82%
Inventory
Prepaid Expenses
Receivables	$8.000K	$12.00K	$271.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$494.0M	$537.2M	$514.2M
YoY Change	-3.46%	4.46%	6.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$53.40M	$54.28M	$56.08M
YoY Change	-4.38%	-3.22%	1329.26%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$502.0K	$2.840M	$2.430M
YoY Change	-69.11%	16.87%	21.62%
Total Long-Term Assets	$69.26M	$69.49M	$67.75M
YoY Change	2.95%	2.58%	635.09%
TOTAL ASSETS
Total Short-Term Assets	$494.0M	$537.2M	$514.2M
Total Long-Term Assets	$69.26M	$69.49M	$67.75M
Total Assets	$563.3M	$606.6M	$582.0M
YoY Change	-2.71%	4.24%	18.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.05M	$11.59M	$6.254M
YoY Change	-19.87%	85.32%	-20.81%
Accrued Expenses	$14.10M	$20.20M	$25.50M
YoY Change	-43.6%	-20.78%	94.66%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.500M	$1.100M
YoY Change
Total Short-Term Liabilities	$46.13M	$35.56M	$33.68M
YoY Change	16.5%	5.57%	44.96%
LONG-TERM LIABILITIES
Long-Term Debt	$50.70M	$51.10M	$0.00
YoY Change
Other Long-Term Liabilities	$110.5M	$110.5M	$52.00M
YoY Change	110.88%	112.5%	41169.84%
Total Long-Term Liabilities	$161.2M	$161.6M	$52.02M
YoY Change	207.41%	210.61%	2167.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$46.13M	$35.56M	$33.68M
Total Long-Term Liabilities	$161.2M	$161.6M	$52.02M
Total Liabilities	$207.3M	$197.1M	$85.70M
YoY Change	125.26%	130.03%	235.72%
SHAREHOLDERS EQUITY
Retained Earnings	-$551.0M	-$491.1M	-$324.5M
YoY Change	61.01%	51.34%	107.18%
Common Stock	$398.0K	$398.0K	$380.0K
YoY Change	4.19%	4.74%	10.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$356.0M	$409.5M	$496.2M
YoY Change
Total Liabilities & Shareholders Equity	$563.3M	$606.6M	$582.0M
YoY Change	-2.71%	4.24%	18.45%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$59.88M	-$48.74M	-$35.38M
YoY Change	238.3%	37.75%	28.57%
Depreciation, Depletion And Amortization	$800.0K	$797.0K	$759.0K
YoY Change	0.0%	5.01%	202.39%
Cash From Operating Activities	$58.13M	-$31.58M	-$37.84M
YoY Change	-261.11%	-16.54%	51.02%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	-$180.0K	-$2.500M
YoY Change	-52.38%	-92.8%	941.67%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$100.0K
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	-$100.0K	-$181.0K	-$2.399M
YoY Change	-52.38%	-92.46%	907.98%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$150.4M
YoY Change		-100.0%	16.8%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-860.0K	$43.18M	$159.9M
YoY Change	-158.9%	-72.99%	23.97%
NET CHANGE
Cash From Operating Activities	58.13M	-$31.58M	-$37.84M
Cash From Investing Activities	-100.0K	-$181.0K	-$2.399M
Cash From Financing Activities	-860.0K	$43.18M	$159.9M
Net Change In Cash	57.17M	$11.42M	$119.6M
YoY Change	-264.14%	-90.45%	15.4%
FREE CASH FLOW
Cash From Operating Activities	$58.13M	-$31.58M	-$37.84M
Capital Expenditures	-$100.0K	-$180.0K	-$2.500M
Free Cash Flow	$58.23M	-$31.40M	-$35.34M
YoY Change	-262.34%	-11.14%	42.41%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001559053
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39822336	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	Prothena Corp plc
CY2018Q1	dei	Trading Symbol TradingSymbol	PRTA
CY2017Q1	prta	Accrued Offering Costs AccruedOfferingCosts	107000	USD
CY2018Q1	prta	Accrued Offering Costs AccruedOfferingCosts	0	USD
CY2017Q4	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	13509000	USD
CY2018Q1	prta	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	15693000	USD
CY2017Q1	prta	Buildto Suit Leases Increase Decreaseto Obligation BuildtoSuitLeasesIncreaseDecreasetoObligation	501000	USD
CY2018Q1	prta	Buildto Suit Leases Increase Decreaseto Obligation BuildtoSuitLeasesIncreaseDecreasetoObligation	954000	USD
CY2017Q4	prta	Buildto Suit Property Gross BuildtoSuitPropertyGross	51760000	USD
CY2018Q1	prta	Buildto Suit Property Gross BuildtoSuitPropertyGross	51760000	USD
CY2017Q4	prta	Buildtosuit Lease Obligation Current BuildtosuitLeaseObligationCurrent	733000	USD
CY2018Q1	prta	Buildtosuit Lease Obligation Current BuildtosuitLeaseObligationCurrent	1100000	USD
CY2018Q1	prta	Buildtosuit Lease Obligation Currentand Noncurrent BuildtosuitLeaseObligationCurrentandNoncurrent	52202000	USD
CY2017Q4	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	51515000	USD
CY2018Q1	prta	Buildtosuitleaseobligationnoncurrent Buildtosuitleaseobligationnoncurrent	51102000	USD
CY2018Q1	prta	Builtto Suit Leases At Cost BuilttoSuitLeasesAtCost	51800000	USD
CY2017Q1	prta	Collaboration Revenue CollaborationRevenue	259000	USD
CY2018Q1	prta	Collaboration Revenue CollaborationRevenue	227000	USD
CY2017Q4	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2018Q1	prta	Deferred Shares Par Value DeferredSharesParValue	22
CY2017Q4	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2018Q1	prta	Deferred Shares Share Issued DeferredSharesShareIssued	0	shares
CY2017Q4	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2018Q1	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0.0	shares
CY2018Q1	prta	Deferred Shares Share Outstanding DeferredSharesShareOutstanding	0	shares
CY2017Q4	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2018Q1	prta	Deferred Shares Shares Authorized DeferredSharesSharesAuthorized	10000	shares
CY2017Q4	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2018Q1	prta	Deferred Shares Value DeferredSharesValue	0	USD
CY2017Q1	prta	Interest Expenseunderbuildtosuittransaction InterestExpenseunderbuildtosuittransaction	916000	USD
CY2018Q1	prta	Interest Expenseunderbuildtosuittransaction InterestExpenseunderbuildtosuittransaction	908000	USD
CY2018Q1	prta	Numberof Votes NumberofVotes	1	vote
CY2018Q1	prta	Purchaseand Contractual Obligation Due After Fifth Year PurchaseandContractualObligationDueAfterFifthYear	775000	USD
CY2018Q1	prta	Purchaseand Contractual Obligation Due Next Fiscal Year PurchaseandContractualObligationDueNextFiscalYear	18051000	USD
CY2018Q1	prta	Purchaseand Contractual Obligation Duein Fifth Year PurchaseandContractualObligationDueinFifthYear	85000	USD
CY2018Q1	prta	Purchaseand Contractual Obligation Duein Fourth Year PurchaseandContractualObligationDueinFourthYear	100000	USD
CY2018Q1	prta	Purchaseand Contractual Obligation Duein Second Year PurchaseandContractualObligationDueinSecondYear	26019000	USD
CY2018Q1	prta	Purchaseand Contractual Obligation Duein Third Year PurchaseandContractualObligationDueinThirdYear	100000	USD
CY2018Q1	prta	Purchaseand Contractual Obligation Total PurchaseandContractualObligationTotal	45130000	USD
CY2017Q1	prta	Receivablefrom Option Exercises ReceivablefromOptionExercises	311000	USD
CY2018Q1	prta	Receivablefrom Option Exercises ReceivablefromOptionExercises	19000	USD
CY2017Q1	prta	Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision	-1900000	USD
CY2018Q1	prta	Sharebased Compensation Net Tax Shortfall Excess Tax Benefit Amount Bookedto Income Tax Provision SharebasedCompensationNetTaxShortfallExcessTaxBenefitAmountBookedtoIncomeTaxProvision	300000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13633000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	11590000	USD
CY2017Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	0	USD
CY2018Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	100000000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	240000	USD
CY2018Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	12000	USD
CY2017Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	311000	USD
CY2018Q1	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	481000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	438000	USD
CY2018Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	654000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7743000	USD
CY2018Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8540000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	849154000	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	900200000	USD
CY2017Q4	us-gaap	Assets Assets	496329000	USD
CY2018Q1	us-gaap	Assets Assets	606647000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	426327000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	537153000	USD
CY2017Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	70002000	USD
CY2018Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	69494000	USD
CY2017Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1316000	USD
CY2018Q1	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1395000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	506550000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	417620000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	429039000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	390979000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	510606000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	421676000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	433095000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	119627000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	11419000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	38482764	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39821799	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39821799	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	38482764	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39821799	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39821799	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	385000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	398000	USD
CY2017Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	737000	USD
CY2018Q1	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	395000	USD
CY2017Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	49000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2018Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	110242000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	8113000	USD
CY2018Q1	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	8320000	USD
CY2018Q1	us-gaap	Deferred Rent Credit DeferredRentCredit	49000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	254000	USD
CY2018Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	243000	USD
CY2017Q1	us-gaap	Depreciation Depreciation	800000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	800000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	759000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	797000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.99
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.26
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7342000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4475000	USD
CY2017Q1	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	2096000	USD
CY2018Q1	us-gaap	Gain Loss On Contract Termination GainLossOnContractTermination	0	USD
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10832000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	14229000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-37045000	USD
CY2018Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-48780000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1661000	USD
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-37000	USD
CY2017	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	-400000	USD
CY2017Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2018Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2831000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2735000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	93000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	99772000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
CY2018Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	110242000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	5452000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-422000	USD
CY2017Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-364000	USD
CY2018Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	200000	USD
CY2017Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	579000	USD
CY2018Q1	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	579000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	89140000	USD
CY2018Q1	us-gaap	Liabilities Liabilities	197142000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	496329000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	606647000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	37371000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	35555000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-37842000	USD
CY2017Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	51769000	USD
CY2018Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	161587000	USD
CY2017Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9078000	USD
CY2018Q1	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	9084000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	159868000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	43184000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2399000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-181000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-31584000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-35384000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-48743000	USD
CY2017Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	88000	USD
CY2018Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	79000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-774000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-72000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	36530000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	48935000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-36271000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-48708000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1951000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	255000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	255000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	255000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	255000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	680000	USD
CY2018Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	251000	USD
CY2017Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
CY2018Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	200000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2843000	USD
CY2018Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2840000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	9185000	USD
CY2018Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	6691000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-410000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-272000	USD
CY2017Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1356000	USD
CY2018Q1	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	1513000	USD
CY2017Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	2499000	USD
CY2018Q1	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	181000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8467000	USD
CY2018Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8102000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	150421000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	39758000	USD
CY2018Q1	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	0	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	100000	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2017Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9948000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4380000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	62733000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	62818000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	54990000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	54278000	USD
CY2018Q1	us-gaap	Purchase Obligation PurchaseObligation	43405000	USD
CY2018Q1	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2018Q1	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	0	USD
CY2018Q1	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	25789000	USD
CY2018Q1	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	0	USD
CY2018Q1	us-gaap	Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear	17616000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25698000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34706000	USD
CY2017Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4056000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4056000	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	4056000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-442350000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-491093000	USD
CY2017Q1	us-gaap	Revenues Revenues	259000	USD
CY2018Q1	us-gaap	Revenues Revenues	227000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	5602000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	6902000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	407189000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	409505000	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	35758000	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38684000	shares
CY2018Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment and Concentration of Risks</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in one segment. The Company’s chief operating decision maker (the “CODM”), its Chief Executive Officer, manages the Company’s operations on a consolidated basis for purposes of allocating resources. When evaluating the Company’s financial performance, the CODM reviews all financial information on a consolidated basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. The Company places its cash equivalents with high credit quality financial institutions and by policy, limits the amount of credit exposure with any one financial institution. Deposits held with banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses on its deposits of cash and cash equivalents and its credit risk exposure is up to the extent recorded on the Company's Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The receivable from Celgene Switzerland LLC (“Celgene”) as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> relates to the upfront payment under the Master Collaboration Agreement that became effective </font><font style="font-family:inherit;font-size:10pt;">March 20, 2018</font><font style="font-family:inherit;font-size:10pt;">. Celgene is wholly owned by Celgene Switzerland SA, a tax resident of Switzerland. The receivable from Roche as of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are amounts due from Roche entities located in the U.S. and Switzerland under the License Agreement that became effective January 22, 2014. Revenue recorded in the Statements of Operations consists of reimbursement from Roche for research and development services. The Company's credit risk exposure is up to the extent recorded on the Company's Condensed Consolidated Balance Sheet.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> As of </font><font style="font-family:inherit;font-size:10pt;">March 31, 2018</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$53.7 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's long-lived assets were held in the U.S. and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> were in Ireland. As of </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$54.4 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's long-lived assets were held in the U.S. and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> were in Ireland.</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company does not own or operate facilities for the manufacture, packaging, labeling, storage, testing or distribution of nonclinical or clinical supplies of any of its drug candidates, including for commercial supplies if the Company obtains regulatory approval to market any of its drug candidates. The Company instead contracts with and relies on third-parties to manufacture, package, label, store, test and distribute all pre-clinical development and clinical supplies of our drug candidates, and it plans to continue to do so for the foreseeable future, including for commercial supplies if the Company obtains regulatory approval to market any of its drug candidates. The Company also relies on third-party consultants to assist in managing these third-parties and assist with its manufacturing strategy.</font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, share-based compensation and research and development expenses. The Company bases its estimates on historical experience and on various other market specific and other relevant assumptions that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Because of the uncertainties inherent in such estimates, actual results may differ materially from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001559053-18-000014-index-headers.html	Edgar Link	pending
0001559053-18-000014-index.html	Edgar Link	pending
0001559053-18-000014.txt	Edgar Link	pending
0001559053-18-000014-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
prothenassaexecutionv_image1.jpg	Edgar Link	pending
prta-20180331.xml	Edgar Link	completed
prta-20180331.xsd	Edgar Link	pending
prta-20180331_cal.xml	Edgar Link	unprocessable
prta-20180331_def.xml	Edgar Link	unprocessable
prta-20180331_lab.xml	Edgar Link	unprocessable
prta-20180331_pre.xml	Edgar Link	unprocessable
prta2018q110-q.htm	Edgar Link	pending
prta2018q110-qex101aucsdli.htm	Edgar Link	pending
prta2018q110-qex101bucsdli.htm	Edgar Link	pending
prta2018q110-qex102uhnexcl.htm	Edgar Link	pending
prta2018q110-qxex103prothe.htm	Edgar Link	pending
prta2018q110-qxex104celgen.htm	Edgar Link	pending
prta2018q110-qxex311.htm	Edgar Link	pending
prta2018q110-qxex312.htm	Edgar Link	pending
prta2018q110-qxex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta

2018 Q2 Form 10-Q Financial Statement

#000155905318000014 Filed on May 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA PROTHENA CORP PUBLIC LTD CO Stock $prta

2018 Q2 Form 10-Q Financial Statement

#000155905318000014 Filed on May 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PRTA
PROTHENA CORP PUBLIC LTD CO Stock $prta